BIOLASE Announces Regulatory Clearance of Laser Bacterial Reduction Therapy Indication for Epic Hygiene Laser
New Indication for Epic Hygiene Laser Provides Highly Effective, Noninvasive Reduction of Bacterial Level and Inflammation
IRVINE, Calif.--BIOLASE, the global leader in dental lasers, is pleased to announce the Epic Hygiene™ laser received regulatory clearance for Laser Bacterial Reduction (LBR) therapy indication from the Food and Drug Administration (FDA). This new indication now allows for the early management of periodontal disease utilizing laser light energy to reduce bacteria and thus decreasing inflammation and enhancing periodontal health.
The Epic Hygiene laser, designed specifically for dental hygienists by dental hygienists, has continued to arm the hygienist community with more access to the advantages of laser technology since it was first introduced in December 2019. The new indication allows hygienists to perform gentler, highly effective treatments for bacterial reduction and managing periodontal disease.
"We are extremely pleased that this new indication has been cleared by the FDA for the Epic Hygiene Laser," said BIOLASE CEO, Todd Norbe. "With this clearance, we can further expand the types of procedures hygienists can perform, directly aligning with our mission of advancing dentistry across all fields. We also believe this new indication will directly benefit patients by providing a virtually-pain free and faster treatment option."
In addition to the reduction of bacterial level and inflammation, the Epic Hygiene laser has also received clearance for the removal of highly inflamed edematous tissue affected by bacteria penetration of the pocket lining and junctional epithelium.
To learn more about the Epic Hygiene laser, visit go.biolase.com/EpicHygiene or call 855-292-5690